Table 1. Baseline characteristics of ALLHAT study participants followed for cancer mortality in (trial and post-trial combined) stratified by estimated glomerular filtration rate (eGFR).
| Estimated glomerular filtration rate (mL/min/1.73 m2) | ||||||
|---|---|---|---|---|---|---|
| Total | ≥ 90 | 89.9 – 60 | 59.9 – 45 | < 45 | p-value | |
| N* | 31,349 | 8,027 | 17,778 | 4,293 | 1,251 | |
| Age – mean years (SD) | 66.9 (7.7) | 63.3 (6.4) | 67.3 (7.5) | 70.5 (7.6) | 71.7 (8.5) | < 0.001 |
| Women – n (%) | 14,561 (46.5) | 3,752 (46.7) | 7,905 (44.5) | 2,205 (51.4) | 699 (55.9) | < 0.001 |
| Black – n (%) | 10,990 (35.1) | 4,042 (50.4) | 5,438 (30.6) | 1,107 (25.8) | 403 (32.2) | < 0.001 |
| Hispanic – n (%) | 6,086 (19.4) | 1,763 (22.0) | 3,464 (19.5) | 664 (15.5) | 195 (15.6) | < 0.001 |
| Education – mean years (SD) | 11.0 (4.0) | 10.9 (3.9) | 11.1 (4.1) | 10.9 (3.9) | 10.4 (4.1) | < 0.001 |
| Diabetes – n (%) | 12,455 (41.6) | 3,972 (51.2) | 6,453 (38.1) | 1,513 (37.4) | 517 (43.7) | < 0.001 |
| CHD – n (%) | 7,965 (25.6) | 1,682 (21.1) | 4,619 (26.2) | 1,292 (30.4) | 372 (30.0) | < 0.001 |
| ASCVD – n (%) | 16,114 (51.4) | 3,434 (42.8) | 9,353 (52.6) | 2,574 (60.0) | 753 (60.2) | < 0.001 |
| LVH on ECG – n (%) | 5,160 (16.5) | 1,315 (16.4) | 2,912 (16.4) | 714 (16.6) | 219 (17.5) | 0.752 |
| Current or past smoking – n (%) | 19,560 (62.4) | 5,155 (64.2) | 11,097 (62.4) | 2,563 (59.7) | 745 (59.6) | < 0.001 |
| Aspirin – n (%) | 11,320 (36.5) | 2,558 (32.2) | 6,631 (37.7) | 1,657 (38.9) | 474 (38.4) | < 0.001 |
| Estrogen – in women, n (%) | 2,590 (18.1) | 729 (19.8) | 1,439 (18.5) | 349 (16.1) | 73 (10.6) | < 0.001 |
| Body mass index – mean (SD) | 29.7 (6.1) | 30.4 (6.5) | 29.7 (6.0) | 29.2 (5.8) | 28.8 (6.2) | < 0.001 |
| Blood pressure, mmHg – mean (SD) | ||||||
| Systolic | 146.2 (15.7) | 145.9 (15.3) | 146.3 (15.7) | 146.5 (16.3) | 147.0 (16.5) | 0.054 |
| Diastolic | 84.0 (10.1) | 84.9 (9.7) | 84.1 (10.0) | 82.7 (10.5) | 82.0 (10.6) | < 0.001 |
| Pulse, bpm – mean (SD) | 73.5 (10.8) | 74.7 (10.5) | 73.1 (10.7) | 72.9 (11.2) | 74.0 (11.0) | < 0.001 |
| Randomization arm | ||||||
| Chlorthalidone – n (%) | 14,370 (45.8) | 3,606 (44.9) | 8,199 (46.1) | 1,999 (46.6) | 566 (45.2) | 0.225 |
| Amlodipine – n (%) | 8,492 (27.1) | 2,245 (28.0) | 4,768 (26.8) | 1,156 (26.9) | 323 (25.8) | 0.181 |
| Lisinopril – n (%) | 8,487 (27.1) | 2,176 (27.1) | 4,811 (27.1) | 1,138 (26.5) | 362 (28.9) | 0.407 |
| Pravastatin (Lipid Trial) – n (%) | 3,956 (12.6) | 1,047 (13.0) | 2,303 (13.0) | 482 (11.2) | 124 (9.9) | < 0.907 |
| Fasting glucose, mg/dL – mean (SD) | 123.3 (57.5) | 137.3 (67.6) | 118.9 (52.4) | 115.2 (50.0) | 122.3 (63.2) | < 0.001 |
| Potassium, mEq/L – mean (SD) | 4.3 (0.5) | 4.2 (0.5) | 4.3 (0.5) | 4.4 (0.6) | 4.5 (0.6) | < 0.001 |
| Cholesterol, mg/dL – mean (SD) | ||||||
| Total | 216.0 (43.4) | 214.8 (43.5) | 215.2 (41.8) | 219.3 (46.7) | 224.1 (51.3) | < 0.001 |
| LDL | 135.8 (37.1) | 134.7 (37.6) | 135.7 (36.3) | 137.0 (37.3) | 140.9 (43.5) | < 0.001 |
| HDL | 46.8 (14.7) | 48.3 (15.0) | 46.5 (14.5) | 45.9 (14.8) | 45.1 (14.6) | < 0.001 |
| Triglyceride, mg/dL – mean (SD) | 175.9 (134.1) | 169.9 (142.6) | 173.4 (121.9) | 189.3 (155.2) | 202.9 (158.2) | < 0.001 |
*Variable total for education = 29,335; diabetes = 29,922; CHD = 31,108; smoking = 31,348; BMI = 31,253; pulse = 31,303; aspirin = 31,005; estrogen = 14,308; lipid trial = 7,873; glucose = 24,291; potassium = 31,230; cholesterol, total = 31,177, LDL = 29,261, HDL = 31,168, triglycerides = 31,165.